A class of novel N-(3S-1,2,3,4-tetrahydroisoquinoline-3-carbonyl)-L-amino acid derivatives: their synthesis, anti-thrombotic activity evaluation, and 3D QSAR analysis

被引:32
作者
Cheng, Shenling [1 ]
Zhang, Xiaoyi [1 ]
Wang, Wei [2 ]
Zhao, Ming [1 ]
Zheng, Meiqing [1 ]
Chang, Heng Wei [2 ]
Wu, Jianghui [1 ]
Peng, Shiqi [1 ]
机构
[1] Capital Med Univ, Coll Pharmaceut Sci, Beijing 100069, Peoples R China
[2] CS Bio Co, Menlo Pk, CA 94025 USA
基金
中国国家自然科学基金;
关键词
Tetrahydroisoquinoline; Modification; Anti-thrombotic in vivo activity; 3D QSAR; PLATELET-AGGREGATION; MYOCARDIAL-INFARCTION; ANTITUMOR-ACTIVITY; RECEPTOR; ANALOGS; ANTIMALARIAL; ISOQUINOLINE; METABOLITES; MECHANISMS; BIOASSAY;
D O I
10.1016/j.ejmech.2009.08.002
中图分类号
R914 [药物化学];
学科分类号
100705 [微生物与生化药学];
摘要
To find new anti-thrombotic agents, a natural amino acid was introduced into the 3-position of antiplatelet aggregation active 3S-tetrahydroisoquinoline-3-carboxylic acid (THIQA), and 20 novel dipeptide derivatives, 3S-tetrahydroisoquinoline-3-carboxyamino acids (6a-t), targeting the intestinal peptide transport system were provided. In vitro anti-platelet aggregation assay of 6a-t indicated that their potencies of inhibiting adenosine diphosphate (ADP), arachidonic acid (AA), platelet-activating factor (PAF), and thrombin (TH) induced platelet aggregations were higher than that of THIQA, and the in vivo anti-thrombotic assay of 6a-t indicated that their potencies of inhibiting thrombogenesis in rats were also higher than that of THIQA. According to MFA based Cerius2 QSAR module, using training/test set of 6a,b,d,g-p/6c,e,fq and training/test set of 6a-p/6q-t two equations (r, 0.984 and 0.996) correlating the structures with in vitro or in vivo activity of 6a-t were established. (C) 2009 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:4904 / 4919
页数:16
相关论文
共 43 条
[1]
ASHBY B, 1990, HEMATOL ONCOL CLIN N, V4, P1
[2]
Targeting of peptide and protein drugs to specific sites in the oral route [J].
Bai, JPF ;
Chang, LL ;
Guo, JH .
CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 1995, 12 (04) :339-371
[3]
Efficient synthesis and structural analysis of new dioxopiperazine isoquinolines [J].
Cabedo, N ;
El Aouad, N ;
Berenguer, I ;
Zamora, M ;
de Arellano, MCR ;
Suvire, F ;
Bermejo, A ;
Enriz, D ;
Cortes, D .
TETRAHEDRON, 2006, 62 (18) :4408-4418
[4]
Tetrahydroisoquinolines as subtype selective estrogen agonists/antagonists [J].
Chesworth, R ;
Zawistoski, MP ;
Lefker, BA ;
Cameron, KO ;
Day, RF ;
Mangano, M ;
Rosati, RL ;
Colella, S ;
Petersen, DN ;
Brault, A ;
Lu, BH ;
Pan, LC ;
Perry, P ;
Ng, O ;
Castleberry, TA ;
Owen, TA ;
Brown, TA ;
Thompson, DD ;
DaSilva-Jardine, P .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (11) :2729-2733
[5]
DAVIES MJ, 1990, CIRCULATION, V82, P38
[6]
DAVIES MJ, 1985, BRIT HEART J, V53, P363
[7]
CoMFA and CoMSIA 3D QSAR analysis on N1-arylsulfonylindole compounds as 5-HT6 antagonists [J].
Doddareddy, MR ;
Cho, YS ;
Koh, HY ;
Pae, AN .
BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (15) :3977-3985
[8]
ESZARICSRIEDL Z, 2006, EUR J MED CHEM, V41, P445
[9]
PLATELET ACTIVATION IN UNSTABLE CORONARY-DISEASE [J].
FITZGERALD, DJ ;
ROY, L ;
CATELLA, F ;
FITZGERALD, GA .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 315 (16) :983-989
[10]